Брахитерапия при органосохраняющем лечении рака мочевого пузыря

Рак мочевого пузыря занимает 9-е место по распространенности злокачественных новообразований во всем мире. Мышечно-инвазивный рак мочевого пузыря – агрессивное злокачественное новообразование со склонностью к раннему метастазированию. Основной метод лечения данной патологии – радикальная цистэктомия с лимфодиссекцией и полихимотерапией. В последние десятилетия активно рассматривается органосохраняющая консервативная терапия. На сегодняшний день существует наиболее изученный подход к органосохраняющему лечению мышечно-инвазивного рака мочевого пузыря – метод тримодальной терапии, включающий трансуретральную резекцию стенки мочевого пузыря с опухолью, химиотерапию и дистанционную лучевую терапию. В статье представлен подход, включающий и внутриопухолевую лучевую терапию. В работе мы изучили современное состояние брахитерапии в лечении рака мочевого пузыря и путь становления данного метода лечения.

1. Barringer B.S. Radium treatment of carcinoma of the bladder. Ann Surg 1921;74(6):751–67.

2. Orton C.G., Seyedsadr M., Somnay A. Comparison of high and low dose rate remote afterloading for cervix cancer and the importance of fractionation. Int J Radiat Oncol Biol Phys 1991;21(6):1425–34. DOI: 10.1016/0360-3016(91)90316-v

3. Herger C., Sauer H.R. Radium treatment of cancer of bladder. Report of 267 cases. Am J Roentgenol 1942;47:909–15.

4. Van der Werf-Messing B. Treatment of carcinoma of the bladder with radium. Clin Radiol 1965;16:16–26. DOI: 10.1016/s0009-9260(65)80029-0

5. Van der Werf-Messing B., Star W.M., Menon R.S. T3NXM0 carcinoma of the urinary bladder treated by the combination of radium implant and external irradiation. A preliminary report. Int J Radiat Oncol Biol Phys 1980;6(12):1723–5. DOI: 10.1016/0360-3016(80)90259-x

6. Wijnmaalen A., van der Werf-Messing B.H. Factors influencing the prognosis in bladder cancer. Int J Radiat Oncol Biol Phys 1986;12(4):559–65. DOI: 10.1016/0360-3016(86)90063-5

7. Morson A.C. Observations on twenty-three cases of carcinoma of the bladder treated by radium. Br Med J 1929;1(3570):1038–9. DOI: 10.1136/bmj.1.3570.1038

8. Lenz M., Cahill G.F. The treatment of cancer of the bladder by radium needles. Am J Roentgenol Radium Ther 1947;58(4):486–92.

9. Barringer B.S. Twenty-five years of radon treatment of cancer of the bladder. J Am Med Assoc 1947;135(10):616–8. DOI: 10.1001/jama.1947.02890100010003

10. Van der Werf-Messing B., Menon R.S., Hop W.C.J. Cancer of the urinary bladder category T2, T3, (NXM0) treated by interstitial radium implant: second report. Int J Radiat Oncol Biol Phys 1983;9(4):481–5. DOI: 10.1016/0360-3016(83)90064-0

11. Van der Werf-Messing B.H., Van Putten W.L. Carcinoma of the urinary bladder category T2,3NXM0 treated by 40 Gy external irradiation followed by cesium137 implant at reduced dose (50 %). Int J Radiat Oncol Biol Phys 1989;16(2):369–71. DOI: 10.1016/0360-3016(89)90332-5

12. Mazeron J.J., Crook J., Chopin D. et al. Conservative treatment of bladder carcinoma by partial cystectomy and interstitial iridium 192. Int J Radiat Oncol Biol Phys 1988;15(6):1323–30. DOI: 10.1016/0360-3016(88)90227-1

13. De Neve W., Lybeert M.L., Goor C. et al. T1 and T2 carcinoma of the urinary bladder: Long term result with external, preoperative, or interstitial radiotherapy. Int J Radiat Oncol Biol Phys 1992;23(2):299–304. DOI: 10.1016/0360-3016(92)90745-4

14. Battermann J.J., Tierie A.H. Results of implantation for T1 and T2 bladder tumours. Radiother Oncol 1986;5(2):85–90. DOI: 10.1016/s0167-8140(86)80161-x

15. Pernot M., Hubert J., Guillemin F. et al. Combined surgery and brachytherapy in the treatment of some cancers of the bladder (partial cystectomy and interstitial iridium-192). Radiother Oncol 1996;38(2):115–20. DOI: 10.1016/0167-8140(96)82354-1

16. Wijnmaalen A., Helle P.A., Koper P.C. et al. Muscle invasive bladder cancer treated by transurethral resection, followed by external beam radiation and interstitial iridium-192. Int J Radiat Oncol Biol Phys 1997;39(5):1043–52. DOI: 10.1016/s0360-3016(97)00375-1

17. De Crevoisier R., Ammor A., Court B. et al. Bladder-conserving surgery and interstitial brachytherapy for lymph node negative transitional cell carcinoma of the urinary bladder: Results of a 28-year single institution experience. Radiother Oncol 2004;72(2):147–57. DOI: 10.1016/j.radonc.2004.06.002

18. Nieuwenhuijzen J.A., Pos F., Moonen L.M.F. et al. Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. Eur Urol 2005;48(2):239–45. DOI: 10.1016/j.eururo.2005.03.022

19. Rozan R., Albuisson E., Donnarieix D. et al. Interstitial iridium-192 for bladder cancer (A multicentric survey: 205 patients). Int J Radiat Oncol Biol Phys 1992;24(3):469–77. DOI: 10.1016/0360-3016(92)91061-q

20. Brenner D.J., Hall E.J. Conditions for the equivalence of continuous to pulsed low dose rate brachytherapy. Int J Radiat Oncol Biol Phys 1991;20(1):181–90. DOI: 10.1016/0360-3016(91)90158-z

21. Soete G., Coen V., Verellen D. et al. A feasibility study of high dose rate brachytherapy in solitary urinary bladder cancer. Int J Radiat Oncol Biol Phys 1997;38(4):743–7. DOI: 10.1016/s0360-3016(97)00063-1

22. Pos F.J., Horenblas S., Lebesque J. et al. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer. Int J Radiat Oncol Biol Phys 2004;59(3):696–705. DOI: 10.1016/j.ijrobp.2003.11.040

23. Blank L.E.C.M., Koedooder K., van Os R. et al. Results of bladderconserving treatment, consisting of brachytherapy combined with limited surgery and external beam radiotherapy, for patients with solitary T1-T3 bladder tumors less than 5 cm in diameter. Int J Radiat Oncol Biol Phys 2007;69(2):454–8. DOI: 10.1016/j.ijrobp.2007.03.014

24. Koning C.C.E.,Blank L.E.C.M., Koedooder C. et al. Brachytherapy after external beam radiotherapy and limited surgery preserves bladders for patients with solitary pT1-pT3 bladder tumors. Ann Oncol 2012;23(11):2948–53. DOI: 10.1093/annonc/mds126

25. Smits G.A.H.J., Van der Steen-Banasik E., Oosterveld B. et al. Minimal invasive surgery and brachytherapy as bladder preserving multimodality treatment in selected solitary MIBC. Eur Urol Suppl 2019;18(1):e814. DOI: 10.1016/S1569-9056(19)30594-9

26. Van der Steen-Banasik E.M., Smits G.A.H.J., Oosterveld B.J. et al. The Curie-Da Vinci connection: 5-years’ experience with laparoscopic (robot-assisted) implantation for high-dose-rate brachytherapy of solitary T2 bladder tumors. Int J Radiat Oncol Biol Phys 2016;95(5):1439–42. DOI: 10.1016/j.ijrobp.2016.03.029

27. Bus S.J.E.A., Leus N.G., Oosterveld B.J. et al. An evaluation of our experience in position verification of catheters used for interstitial high-dose-rate brachytherapy of solitary bladder tumors. Brachytherapy 2018;17(1):24–30. DOI: 10.1016/j.brachy.2017.01.013

28. Voskuilen C.S., Bosschieter J., van Werkhoven E. et al. Long-term survival and complications following bladder-preserving brachytherapy in patients with cT1-T2 bladder cancer. Radiother Oncol 2019;141:130–6. DOI: 10.1016/j.radonc.2019.09.026

29. Van Onna I.E.W., Oddens J.R., Kok E.T. et al. External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients. Eur Urol 2009;56(1):113–22. DOI: 10.1016/j.eururo.2008.07.043

30. Van der Steen-Banasik E., Ploeg M., Witjes J.A. et al. Brachytherapy versus cystectomy in solitary bladder cancer: A case control, multicentre, East-Netherlands study. Radiother Oncol 2009;93(2):352–357. DOI: 10.1016/j.radonc.2009.04.020

31. Aluwini S., Van Rooij P.H.E., Kirkels W.J. et al. Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surger in bladder cancer patients: Long-term results. Int J Radiat Oncol Biol Phys 2014;88(3):611–7. DOI: 10.1016/j.ijrobp.2013.11.227

32. Krasnow R.E., Drumm M., Roberts H.J. et al. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. Eur Urol 2017;72(1):54–60. DOI: 10.1016/j.eururo.2016.12.002

33. Han B., Liang S., Jing Y. et al. Organ preservation for muscleinvasive bladder cancer by preoperative intra-arterial chemotherapy and transurethral resection. Med Oncol 2014;31(4):912. DOI: 10.1007/s12032-014-0912-9

34. Mak R.H., Hunt D., Shipley W.U. et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014;32(34):3801–9. DOI: 10.1200/JCO.2014.57.5548

35. Pieters B.R., Van der Steen-Banasik E., Smits G.A. et al. GEC-ESTRO/ACROP recommendations for performing bladdersparing treatment with brachytherapy for muscle-invasive bladder carcinoma. Radiother Oncol 2017;122(3):340–6. DOI: 10.1016/j.radonc.2016.12.022

36. Richtlijn Blaascarcinoom Nederlandstalige samenvatting van de EAU guidelines on bladder cancer. Available at: http://www.nvu.nl